KARS1

<div class="infobox infobox-gene">
<div class="infobox-header">KARS1</div>
<table class="infobox-table">
<tr><th>Gene Symbol</th><td>KARS1</td></tr>
<tr><th>Full Name</th><td>Lysyl-tRNA Synthetase 1</td></tr>
<tr><th>Chromosomal Location</th><td>16q23.3</td></tr>
<tr><th>NCBI Gene ID</th><td>[5751](https://www.ncbi.nlm.nih.gov/gene/5751)</td></tr>
<tr><th>OMIM</th><td>[614421](https://www.omim.org/entry/614421)</td></tr>
<tr><th>Ensembl ID</th><td>[ENSG00000013375](https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000013375)</td></tr>
<tr><th>UniProt</th><td>[Q15020](https://www.uniprot.org/uniprotkb/Q15020/entry)</td></tr>
<tr><th>Associated Diseases</th><td>Charcot-Marie-Tooth disease (CMT) type 2, recessive intermediate neuropathy, mitochondrial disease, hereditary spastic paraplegia, auditory neuropathy</td></tr>
</table>
</div>

KARS1 — Lysyl-tRNA Synthetase 1

Pathway / Mechanism Diagram

Overview

<div class="infobox infobox-gene">
<div class="infobox-header">KARS1</div>
<table class="infobox-table">
<tr><th>Gene Symbol</th><td>KARS1</td></tr>
<tr><th>Full Name</th><td>Lysyl-tRNA Synthetase 1</td></tr>
<tr><th>Chromosomal Location</th><td>16q23.3</td></tr>
<tr><th>NCBI Gene ID</th><td>[5751](https://www.ncbi.nlm.nih.gov/gene/5751)</td></tr>
<tr><th>OMIM</th><td>[614421](https://www.omim.org/entry/614421)</td></tr>
<tr><th>Ensembl ID</th><td>[ENSG00000013375](https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000013375)</td></tr>
<tr><th>UniProt</th><td>[Q15020](https://www.uniprot.org/uniprotkb/Q15020/entry)</td></tr>
<tr><th>Associated Diseases</th><td>Charcot-Marie-Tooth disease (CMT) type 2, recessive intermediate neuropathy, mitochondrial disease, hereditary spastic paraplegia, auditory neuropathy</td></tr>
</table>
</div>

KARS1 — Lysyl-tRNA Synthetase 1

Pathway / Mechanism Diagram

Overview

KARS1 (Lysyl-tRNA Synthetase 1) encodes a crucial enzyme for protein synthesis, catalyzing the attachment of lysine to its cognate tRNA molecule during translation[@kars_overview] [1](https://pubmed.ncbi.nlm.nih.gov/28437156/). This essential function makes KARS1 indispensable for cellular viability across all organisms. However, emerging research has revealed that KARS1, like other aminoacyl-tRNA synthetases (aaRS), possesses diverse extra-translational functions that extend far beyond its canonical role in protein synthesis[@kars_immune] [2](https://doi.org/10.1016/j.tcb.2017.01.003). PMID: 39475571

Mutations in KARS1 have been implicated in several human diseases[@kars_cmt], particularly peripheral neuropathies and mitochondrial disorders, highlighting the critical importance of this enzyme in neuronal health and function [3](https://pubmed.ncbi.nlm.nih.gov/26227153/). The dual functionality of KARS1—serving both as a translation factor and as a signaling molecule—makes it a fascinating target for understanding neurodegenerative disease mechanisms and developing therapeutic interventions. PMID: 26250687

Molecular Structure and Function

Enzyme Architecture

KARS1 is a ~622 amino acid protein with a characteristic bilobal structure typical of class II aminoacyl-tRNA synthetases: PMID: 29874566

The protein exists as both a cytoplasmic form and, through alternative splicing, a mitochondrial form (KARS2 or mtKARS), enabling proper translation in both cellular compartments [4](https://pubmed.ncbi.nlm.nih.gov/21920756/).

Catalytic Mechanism

The aminoacylation reaction proceeds through two-step chemistry:

Step 1: Activation
Lysine + ATP → Lysyl-AMP + PPi

Step 2: Transfer
Lysyl-AMP + tRNA^Lys → Lysyl-tRNA^Lys + AMP

The overall reaction is highly accurate, with error rates less than 1 in 10,000, critical for proper protein synthesis.

Alternative Functions

Beyond translation, KARS1 participates in several non-canonical functions:

Disease Associations

Charcot-Marie-Tooth Disease

KARS1 mutations are a well-established cause of Charcot-Marie-Tooth disease (CMT), a hereditary peripheral neuropathy characterized by progressive muscle weakness and sensory loss:

| Type | Inheritance | Phenotype | Mechanism |
|------|-------------|-----------|------------|
| CMT2 | Autosomal recessive | Intermediate neuropathy | Loss of function |
| CMT-DID | Autosomal recessive | Developmental delay, neuropathy | Compound heterozygous |
| CMT-R | Autosomal recessive | Classical CMT phenotype | Biallelic variants |

The peripheral neuropathy in CMT patients with KARS1 mutations likely results from impaired protein synthesis in axons and Schwann cells, affecting nerve maintenance and regeneration [5](https://pubmed.ncbi.nlm.nih.gov/29440603/).

Mitochondrial Disease

KARS1 variants affecting the mitochondrial-targeted isoform cause mitochondrial translation defects:

• Combined Oxidative Phosphorylation Deficiency: Impaired mitochondrial protein synthesis
• Encephalomyopathy: Progressive encephalopathy with muscle involvement
• Sensorineural Hearing Loss: Mitochondrial dysfunction in inner ear

Hereditary Spastic Paraplegia (HSP)

Specific KARS1 mutations cause pure hereditary spastic paraplegia, characterized by progressive lower limb spasticity and weakness due to upper motor neuron degeneration. This suggests that KARS1 dysfunction particularly affects long corticospinal tract axons [7](https://pubmed.ncbi.nlm.nih.gov/26227153/).

Auditory Neuropathy Spectrum Disorder

KARS1 mutations have been identified in patients with auditory neuropathy, a hearing disorder characterized by preserved outer hair cell function but impaired neural transmission. This reflects the unique vulnerability of the auditory nerve to translational defects.

Neurodevelopmental Disorders

Some KARS1 variants are associated with intellectual disability, developmental delay, and neurological symptoms including:

• Microcephaly
• Ataxia
• Seizures
• Brain malformations

Role in Neurodegeneration

Protein Synthesis Defects

Neurons are particularly dependent on robust protein synthesis for:

KARS1 dysfunction impairs these processes, leading to progressive neuronal dysfunction.

Mitochondrial Dysfunction

The mitochondrial isoform of KARS1 is essential for translating mitochondrial-encoded proteins:

Neurons, with their high energy demands and mitochondrial density, are particularly vulnerable to these defects [9](https://pubmed.ncbi.nlm.nih.gov/25556739/).

Axonal Transport Defects

KARS1 mutations may affect axonal transport through:

• Impaired synthesis of transport proteins
• Mitochondrial dysfunction affecting energy supply
• Direct effects on cytoskeletal proteins

Endoplasmic Reticulum Stress

KARS1 dysfunction triggers ER stress through multiple mechanisms:

Oxidative Stress

Neuronal vulnerability to oxidative stress is exacerbated by KARS1 deficiency:

• Mitochondrial ROS overproduction: Complex I dysfunction leads to increased superoxide
• Impaired antioxidant defenses: Reduced synthesis of antioxidant enzymes
• Lipid peroxidation: Membrane damage from reactive oxygen species
• DNA damage accumulation: 8-oxoguanine lesions in nuclear and mitochondrial DNA

KARS1 in Alzheimer's Disease Pathogenesis

While primarily known for peripheral neuropathies, KARS1 dysfunction contributes to AD pathogenesis through multiple mechanisms [18](https://pubmed.ncbi.nlm.nih.gov/32842276/):

Protein Synthesis Decline:

• Global reduction in translation capacity with aging
• Impaired local protein synthesis at synapses critical for LTP
• Reduced capacity for activity-dependent protein synthesis
• Deficit in long-term potentiation maintenance

• Reduced AMPA and NMDA receptor subunit synthesis
• Impaired scaffolding protein (PSD-95, Homer) production
• Disrupted activity-dependent translation at dendritic spines
• Loss of synaptic connectivity and spine density

• Altered APP processing due to translation defects in secretases
• Effects on BACE1 and γ-secretase component expression
• Potential for increased Aβ production
• Impaired Aβ clearance mechanisms

• Altered translation of MAPT (tau) isoforms
• Effects on tau phosphorylation via dysregulated kinases
• Potential for aggregation-prone species accumulation
• Impaired tau clearance through autophagy

• Reduced mitochondrial protein synthesis
• Impaired complex I and IV assembly
• Energy failure in highly metabolic neurons
• Increased oxidative stress and ROS production

KARS1 in Parkinson's Disease

KARS1 function intersects with PD pathogenesis through several pathways [19](https://pubmed.ncbi.nlm.nih.gov/33152871/):

tRNA Modifications and Translation Fidelity:

• Post-transcriptional tRNA modifications (e.g., queuosine, wybutosine) affect translation fidelity
• Altered tRNA modification patterns in PD substantia nigra
• Implications for α-synuclein (SNCA) protein synthesis
• Error-prone translation leads to protein misfolding and aggregation

• Complex I defects in PD substantia nigra are well-documented
• Critical role of mitochondrial translation in dopaminergic neuron survival
• Energy failure mechanisms underlying neuronal vulnerability
• Particular sensitivity of dopaminergic neurons to translation defects

• Local translation in dopaminergic axons is essential for axonal maintenance
• Axonal protein synthesis requirements in long neuronal projections
• Vulnerability to translation defects in distal axon segments
• Impaired axonal regeneration following injury

• Direct translation of SNCA protein at ribosomes
• Effects of misfolded proteins on translation machinery
• Potential for aggregation seeding due to translation errors
• Autophagy-lysosomal pathway dysfunction from protein overload

• Microglial activation in response to neuronal dysfunction
• Cytokine release affecting neuronal survival
• Chronic neuroinflammation progression
• Feedback loop between neuronal dysfunction and immune response

Therapeutic Implications

Understanding KARS1's role in neurodegeneration suggests several therapeutic approaches:

Expression Pattern

Tissue Distribution

KARS1 is expressed ubiquitously, with highest levels in:

• Brain: Cerebral cortex, hippocampus, cerebellum
• Spinal Cord: Motor neurons
• Peripheral Nerves: Schwann cells, dorsal root ganglia
• Heart: Cardiac muscle
• Skeletal Muscle: Skeletal myocytes
• Liver: Hepatocytes
• Kidney: Tubular cells

Cellular Localization

• Cytoplasm: Main pool for cytoplasmic translation
• Mitochondria: Mitochondrial-targeted isoform
• Nucleus: Some nuclear localization for splicing functions
• Secreted: Can be released extracellularly under certain conditions

Developmental Expression

KARS1 expression is highest during development, consistent with the high protein synthesis demands of growing neurons and developing tissues.

Interaction Network

Protein Interactions

KARS1 interacts with several proteins:

Signaling Pathways

• MTOR Pathway: Links nutrient sensing to translation
• Integrated Stress Response: Global translation control
• Mitochondrial Dynamics: Quality control and biogenesis

Therapeutic Implications

Target Strategies

Challenges

• Blood-Brain Barrier: CNS delivery remains challenging
• Tissue Specificity: Peripheral vs. CNS manifestations
• Dosage Effects: Balancing function across tissues

Research Directions

Current Focus

Future Directions

• Gene Editing: CRISPR-based approaches for precise correction
• Protein Engineering: Enhanced enzyme variants
• Biomarkers: Disease progression markers

Key Publications

Cellular Mechanisms

Translation Fidelity and Quality Control

The accuracy of tRNA charging by KARS1 is critical for proper protein synthesis:

Error Prevention Mechanisms:

Translational fidelity rates exceed 99.99%, with errors occurring less than once per 10,000 codons translated. This precision is essential for neurons, where misfolded proteins can aggregate and trigger stress responses [10](https://pubmed.ncbi.nlm.nih.gov/33234189/).

KARS1 in the Aminoacyl-tRNA Synthetase Complex

KARS1 is part of a larger multisynthetase complex (MSC) that coordinates translation:

Complex Components:

• AIMP1/p43: Scaffolding protein that stabilizes the complex
• AIMP2/p38: Tumor suppressor, regulates cell death
• Other aaRS: EPRS, LARS, IARS, MARS, QARS, RARS, KARS

Isoform-Specific Functions

KARS1 produces multiple isoforms through alternative splicing [12](https://pubmed.ncbi.nlm.nih.gov/21920756/):

| Isoform | Localization | Function |
|---------|--------------|----------|
| KARS1-1 | Cytoplasm | Cytoplasmic translation |
| KARS1-2 | Mitochondria | Mitochondrial translation |
| KARS1-3 | Nucleus | RNA processing |

The mitochondrial isoform (sometimes called KARS2) contains an N-terminal targeting sequence that directs it to the mitochondrial matrix.

Neuropathology

Axonal Degeneration Mechanisms

KARS1 mutations cause axonal degeneration through multiple pathways:

Primary Mechanisms:

Secondary Consequences:

• Wallerian-like degeneration
• Distal axonopathy
• Retrograde degeneration
• Synaptic dysfunction

Glial Cell Interactions

KARS1 deficiency affects not only neurons but also supporting glial cells:

Schwann Cell Impact:

• Impaired myelin maintenance
• Decreased myelination capacity
• Demyelination

• Reduced support for neuronal metabolism
• Altered glutamate handling
• Increased inflammatory responses

Protein Homeostasis Disruption

KARS1 dysfunction leads to broader cellular stress:

Unfolded Protein Response (UPR):

• Accumulation of misfolded proteins
• ER stress signaling
• Translational attenuation

• Reduced autophagy capacity
• Accumulation of damaged organelles
• Impaired aggregate clearance

Genetic Basis

Mutation Spectrum

KARS1 mutations associated with disease include [13](https://pubmed.ncbi.nlm.nih.gov/30345192/):

Mutation Types:

• Missense variants (most common)
• Splice-site mutations
• Nonsense variants (severe phenotype)
• Frameshift insertions/deletions

• Catalytic domain (residues 100-300)
• Editing domain (residues 300-450)
• C-terminal tRNA-binding domain (residues 500-622)

Genotype-Phenotype Correlation

| Mutation Type | Phenotype | Severity |
|--------------|-----------|----------|
| Biallelic missense | CMT2 | Moderate |
| Compound heterozygous | CMT-DID | Moderate-severe |
| Homozygous nonsense | HSP | Severe |
| Heterozygous | Auditor neuropathy | Mild |

Population Genetics

• KARS1 variants have global distribution
• Founder mutations identified in specific populations
• Carrier frequency varies by ethnicity

Diagnostic and Therapeutic Approaches

Diagnosis

Diagnostic Pipeline:

Biomarkers:

• Plasma amino acid levels
• Mitochondrial function assays
• Fibroblast studies

Therapeutic Strategies

Current Approaches [14](https://pubmed.ncbi.nlm.nih.gov/32396864/):

• AAV-mediated KARS1 delivery
• Antisense oligonucleotide approaches
• CRISPR-based gene editing

• Recombinant KARS1 enzyme replacement
• Aminoacyl-tRNA synthetase boosters

• Translational fidelity enhancers
• Mitochondrial protectors
• Neuroprotective agents

• Physical therapy
• Orthopedic interventions
• Assistive devices

Clinical Trials

No KARS1-specific clinical trials exist as of 2025, but broader trials include:

• Charcot-Marie-Tooth disease gene therapy trials
• Mitochondrial disease treatment trials
• Peripheral neuropathy therapeutic trials

Model Systems

Animal Models

ZebraFish Models:

• kars morphant phenotype
• Knockout models showing neuropathy
• Drug screening platforms

• Conditional knockout in neurons
• Tissue-specific deletion
• Phenotype characterization ongoing

Cell Culture Models

Patient-Derived Models [15](https://pubmed.ncbi.nlm.nih.gov/31530982/):

• iPSC-derived neurons
• Patient fibroblasts
• Engineered cell lines

Biochemical Studies

• Purified protein characterization
• Enzyme kinetics analysis
• Structure-function studies

Comparative Biology

Evolutionary Conservation

KARS1 is highly conserved across species:

• Bacteria to humans
• Essential for viability
• Both cytosolic and mitochondrial forms

Species-Specific Features

| Species | Features |
|---------|----------|
| C. elegans | Single KARS, both functions |
| Drosophila | Separate cytosolic/mitochondrial |
| Zebrafish | Orthologous functions |
| Mouse | Highly similar to human |
| Humans | Alternative splicing complexity |

Future Directions

Research Priorities

Emerging Technologies

• Single-cell RNA sequencing
• Proteomics approaches
• Advanced imaging techniques
• Organoid models

Collaborative Efforts

• International CMT registries
• KARS1 variant databases
• Patient advocacy groups
• Research consortiums

Molecular Interactions and Signaling Networks

KARS1 in Cellular Stress Responses

KARS1 participates in multiple cellular stress response pathways beyond its canonical translation functions:

Integrated Stress Response (ISR):
The Integrated Stress Response is activated by various cellular stresses including ER stress, mitochondrial dysfunction, and nutrient deprivation. KARS1 plays a role in this pathway through its requirement for global protein synthesis during stress recovery. When cells experience stress, global translation is attenuated through eIF2α phosphorylation, but specific stress-response proteins are still synthesized. KARS1's activity is essential for translating these crucial stress-response proteins, making it a critical component of cellular survival mechanisms.

ER Stress and Unfolded Protein Response:
The ER is particularly sensitive to perturbations in protein folding capacity. KARS1 mutations can contribute to ER stress through:

• Accumulation of mistranslated proteins
• Impaired folding capacity
• Activation of downstream stress signaling

• Antioxidant gene activation (Nrf2 pathway)
• Mitochondrial quality control (mitophagy)
• Metabolic adaptation

KARS1 and the Proteostasis Network

The cellular protein homeostasis network coordinates protein synthesis, folding, quality control, and degradation:

Molecular Chaperone Interactions:
KARS1 interacts with several chaperone systems:

• HSP70 family: Assists in protein folding
• HSP90 family: Manages mature protein complexes
• Chaperonin TRiC/CCT: Folds cytoskeletal proteins

• Ubiquitin-Proteasome System: Degrades misfolded proteins
• Autophagy-Lysosome Pathway: Clears aggregates and damaged organelles

KARS1 in Neuronal Specific Pathways

Neurons have unique requirements for KARS1 function:

Local Translation in Axons:
Axons contain specialized translation machinery for local protein synthesis. KARS1 is required for:

• Cytoskeletal maintenance proteins
• Transport proteins (kinesins, dyneins)
• Synaptic protein precursors
• Mitochondrial proteins for local energy production

• Receptor trafficking and recycling
• Scaffolding protein replacement
• Neurotransmitter release machinery
• Postsynaptic density maintenance

• Myelin basic protein (MBP) production
• Myelin protein zero (MPZ)
• Peripheral myelin protein 22 (PMP22)

Clinical Management

Patient Evaluation

Clinical Features:

• Progressive distal weakness
• Sensory loss
• Foot deformities (pes cavus, hammertoes)
• Reduced or absent reflexes
• Variable age of onset

Management Strategies

Multidisciplinary Care:

• Neurology
• Physical/Occupational Therapy
• Orthopedic Surgery
• Pain Management
• Genetic Counseling

• Strengthening exercises
• Balance training
• Gait optimization
• Assistive devices

• Disease progression tracking
• Respiratory function (in severe cases)
• Cardiac function (in mitochondrial forms)
• Hearing evaluation

Emerging Therapies

Gene Replacement Therapy:
AAV vectors can deliver functional KARS1 to affected tissues. Challenges include:

• Achieving sufficient expression
• Targeting both CNS and peripheral nervous system
• Avoiding immune response

• Translation fidelity enhancers: Improve accuracy
• Mitochondrial protectants: Support energy metabolism
• Neuroprotective compounds: Enhance neuronal survival

• Splice-correcting ASOs
• NMD-blocking ASOs for nonsense variants

Public Health and Research Infrastructure

Epidemiology

• CMT affects approximately 1 in 2500 people
• KARS1 accounts for ~1-2% of CMT cases
• Both sporadic and familial cases reported

Patient Registries

• Charcot-Marie-Tooth Research Foundation
• Inherited Neuropathy Consortium
• Rare Disease registries

Research Funding

• NIH research grants
• Foundation funding
• Industry partnerships

Summary

KARS1 (Lysyl-tRNA Synthetase 1) is an essential enzyme for protein synthesis with critical roles in both cytoplasmic and mitochondrial translation. Its involvement in multiple neurodegenerative diseases, particularly Charcot-Marie-Tooth disease and hereditary spastic paraplegia, highlights its importance for neuronal health. The dual functionality of KARS1 as both a translation factor and signaling molecule makes it a fascinating target for understanding disease mechanisms and developing therapeutics. As research advances, KARS1 continues to provide insights into the fundamental processes of neuronal function and dysfunction.

References (Full List)

See Also

• [Charcot-Marie-Tooth Disease](/diseases/charcot-marie-tooth-disease)
• [Hereditary Spastic Paraplegia](/diseases/hereditary-spastic-paraplegia)
• [Mitochondrial Disease](/diseases/mitochondrial-disease)
• [Aminoacyl-tRNA Synthetases](/entities/aminoacyl-trna-synthetases)
• [Protein Synthesis](/mechanisms/protein-synthesis)
• [Peripheral Neuropathy](/diseases/peripheral-neuropathy)
• [Mitochondrial Translation](/mechanisms/mitochondrial-translation)
• [Translation Machinery](/mechanisms/translation-machinery)

References (Full List)

External Links

• [NCBI Gene: KARS1](https://www.ncbi.nlm.nih.gov/gene/5751)
• [Ensembl: ENSG00000013375](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000013375)
• [UniProt: Q15020](https://www.uniprot.org/uniprotkb/Q15020/entry)
• [OMIM: 614421](https://www.omim.org/entry/614421)

KARS1 in Alzheimer's and Parkinson's Disease

Alzheimer's Disease

While primarily known for peripheral neuropathies, KARS1 dysfunction may contribute to AD pathogenesis through multiple mechanisms [18](https://pubmed.ncbi.nlm.nih.gov/32842276/):

Protein Synthesis Decline:

• Global reduction in translation capacity with aging
• Impaired local protein synthesis at synapses
• Reduced capacity for activity-dependent protein synthesis

• Altered translation of tau isoforms
• Effects on tau post-translational modifications
• Potential for aggregation-prone species accumulation

• Reduced AMPA and NMDA receptor subunit synthesis
• Impaired scaffolding protein production
• Disrupted activity-dependent translation

Parkinson's Disease

KARS1 function intersects with PD pathogenesis through several pathways [19](https://pubmed.ncbi.nlm.nih.gov/33152871/):

tRNA Modifications:

• Post-transcriptional tRNA modifications affect translation fidelity
• Modified tRNAs in PD brains
• Implications for α-synuclein synthesis

• Complex I defects in PDsubstantia nigra
• Role of mitochondrial translation in dopaminergic survival
• Energy failure mechanisms

• Local translation in dopaminergic axons
• Axonal maintenance requirements
• Vulnerability to translation defects

Editing Function and Disease

The editing domain of KARS1 prevents misaminoacylation [10](https://pubmed.ncbi.nlm.nih.gov/29278441/):

Editing Mechanism

Disease Relevance

• Editing domain mutations cause CMT
• Reduced editing leads to toxic misfolded proteins
• Mislocalized amino acids cause cellular stress

Multisynthetase Complex

KARS1 functions within the multisynthetase complex (MSC) [11](https://pubmed.ncbi.nlm.nih.gov/25825857/):

Complex Components

| Component | Function |
|-----------|----------|
| KARS1 | Lysyl-tRNA synthesis |
| EARS | Glutamyl-tRNA synthesis |
| RARS | Arginyl-tRNA synthesis |
| AIMP1 | Scaffold protein |
| AIMP2 | Scaffold protein |

Functional Implications

• Efficient tRNA aminoacylation
• Channeling of charged tRNAs to ribosomes
• Coordinated regulation of translation

Extracellular Functions

KARS1 has cytokine-like functions when secreted [12](https://pubmed.ncbi.nlm.nih.gov/27354479/):

Immune Modulation

• Extracellular KARS1 activates immune cells
• Cytokine-like signaling
• Wound healing functions

Implications for Neuroinflammation

• Released from damaged neurons
• Microglial activation
• Chronic neuroinflammation in neurodegeneration

Axonal Protein Synthesis

KARS1's role in axonal translation is critical for neuronal function [13](https://pubmed.ncbi.nlm.nih.gov/25027053/), [14](https://pubmed.ncbi.nlm.nih.gov/25593275/):

Local Translation Requirements

Translation Regulation

• mTOR-dependent regulation
• Activity-dependent translation
• Stress granule formation
• Integrated stress response

Therapeutic Approaches

Multiple strategies are being developed for aaRS-related disorders [15](https://pubmed.ncbi.nlm.nih.gov/31974247/):

Gene Therapy

• AAV-mediated KARS1 delivery
• CRISPR-based gene correction

Small Molecule Approaches

• Enzyme activators
• Translation fidelity modulators
• Mitochondrial function enhancers

Supportive Therapies

• CoQ10 supplementation
• L-carnitine
• Neuroprotective agents

Biomarker Development

[17](https://pubmed.ncbi.nlm.nih.gov/34099567/) KARS1 as a biomarker:

• Blood KARS1 levels
• CSF analysis
• Disease progression markers

Updated References